Prostate cancer incidence, clinical stage and survival in relation to obesity: A prospective cohort study in Denmark

International Journal of Cancer

Volumn 136, Issue 8, 2015, Pages 1940-1947

  Møller, Henrik ^a,b,c   Roswall, Nina ^d   Hemelrijck, Mieke Van ^a   Larsen, Signe Benzon ^d   Cuzick, Jack ^b   Holmberg, Lars ^a,e   Overvad, Kim ^c   Tjønneland, Anne ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cohort study; Denmark; Obesity; Prostate cancer; Survival

Indexed keywords

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY HEIGHT; BODY MASS; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FATALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PROSPECTIVE STUDY; PROSTATE CANCER; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; BODY WEIGHT; COMPLICATION; INCIDENCE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR;

ADIPOSE TISSUE; BODY MASS INDEX; BODY WEIGHT; DENMARK; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 84922575904     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29238     Document Type: Article

References (35)

1. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol 2013;63:800-9.
2. Fowke JH, Motley SS, Concepcion RS, et al. Obesity, body composition, and prostate cancer. BMC Cancer 2012;12:23.
3. Pischon T, Boeing H, Weikert S, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008;17:3252-61.
4. Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer 2012;131:1711-9.
5. Stocks T, Hergens MP, Englund A, et al. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer 2010;127:1660-8.
6. Discacciati A, Orsini N, Andersson SO, et al. Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 2011;105:1061-8.
7. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Ann Oncol 2012;23:1665-71.
8. Cao Y, Ma J. Body mass index, prostate cancerspecific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2011;4:486-501.
9. Pelucchi C, Serraino D, Negri E, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol 2011;21:835-41.
10. Lewis SJ, Murad A, Chen L, et al. Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 2010;5:e13485.
11. Häggström C, Stocks T, Ulmert D, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer 2012;118:6199-206.
12. Outzen M, Brasso K, Martinussen N, et al. Prostate cancer in Denmark 1978-2009-trends in incidence and mortality. Acta Oncol 2013;52:831-6.
13. Larsen SB, Brasso K, Iversen P, et al. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. Eur J Cancer 2013;49:3041-8.
14. Tjønneland A, Olsen A, Boll K, et al. Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: a population-based prospective cohort study of 57, 053 men and women in Denmark. Scand J Public Health 2007;35:432-41.
15. Egeberg R, Olsen A, Christensen J, et al. Intake of whole-grain products and risk of prostate cancer among men in the Danish Diet, Cancer and Health cohort study. Cancer Causes Control 2011;22:1133-9.
16. Stegger JG, Schmidt EB, Obel T, et al. Body composition and body fat distribution in relation to later risk of acute myocardial infarction: a Danish follow-up study. Int J Obes (Lond) 2011;35:1433-41.
17. Roswall N, Larsen SB, Friis S, et al. Micronutrient intake and risk of prostate cancer in a cohort of middle-aged, Danish men. Cancer Causes Control 2013;24:1129-35.
18. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008;359:2105-20.
19. Chu DI, De Nunzio C, Gerber L, et al. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis 2011;14:346-53.
20. Wilson KM, Giovannucci EL, Mucci LA. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012;14:365-74.
21. Zadra G, Photoopoulos C, Loda M. The fat side of prostate cancer. Biochim Biophys Acta 2013;1831:1518-32.
22. Swinnen JV, Heemers H, Van De Sande T, et al. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 2004;92:273-9.
23. Tanioka T, Nakatani Y, Semmyo N, et al. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-82.
24. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296:2232-5.
25. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castrationresistant prostate cancer. Cancer Res 2008;68:6407-15.
26. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
27. Nguyen PL, Ma J, Chavarro JE, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol 2010;28:3958-64.
28. Flavin R, Zadra G, Loda M. Metabolic alterations and targeted therapies in prostate cancer. J Pathol 2011;223:283-94.
29. De Nunzio C, Aronson W, Freedland SJ, et al. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70.
30. Bhindi B, Locke J, Alibhai SM, et al. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol, in press.
31. Pettersson A, Lis RT, Meisner A, et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst 2013;105:1881-90.
32. Chamberlain C, Romundstad P, Vatten L, et al. The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort. Int J Cancer 2011;129:1199-206.
33. https://www.ukbiobank.ac.uk/.
34. Cuzick J, Berney DM, Fisher G, et al.; Transatlantic Prostate Group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095-9.
35. Berney DM, Fisher G, Kattan MW, et al.; Trans-Atlantic Prostate Group. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007;100:1240-4.